// App-Quantinova.ai

SAT0186 : DEVELOPING PREDICTORS OF GLOBAL BILAG TREATMENT RESPONSE IN PATIENTS WITH LUPUS NEPHRITIS: MORE LESSONS FROM THE ASPREVA LUPUS MANAGEMENT STUDY GROUP (ALMS) DATA

Researchers

Presenter

  • S. Mcdonald

Principal Investigators

  • S. Yiu

  • L. Su

  • C. Gordon

  • N. Solomons

  • I. N. Bruce

Medical Centers

  • University of Manchester, NIHR Manchester BRC, Manchester, United Kingdom

  • University of Cambridge, MRC Biostatistics Unit, School of Clinical Medicine, Cambridge Institute of Public Health, Cambridge, United Kingdom

  • University of Birmingham, Institute of Inflammation and Ageing, Birmingham, UK

  • Aurinia Pharmaceuticals Inc., Victoria, BC, Canada

  • Manchester University NHS FT, Manchester Academic Health Science Centre, Manchester, United Kingdom

Locations

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Lupus nephritis

  • Alstrom syndrome

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved